NioCorp to be added to Russell 3000 Index
NioCorp (NB) announced that it will be added as a member of the broad-market Russell 3000 Index, effective after the U.S. market opens on June 30 as part of the 2025 Russell indexes reconstitution.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
44 minutes ago
- Business Wire
DiaMedica Therapeutics Announces Inclusion in the Russell 2000 ® and Russell 3000 ® Indexes
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic stroke, today announced its upcoming addition as a member of the US small-cap Russell 2000 and Russell 3000 Indexes, effective after the U.S. market closes on June 27. The Russell 3000 Index encompasses the 3,000 largest U.S. companies by market capitalization, representing approximately 98% of the investable U.S. equity market. The Russell 2000 Index is a subset of the Russell 3000, measuring the performance of the small-cap segment. These indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. 'DiaMedica's inclusion in the Russell 2000 and Russell 3000 indexes marks an important milestone in our company's journey,' said Rick Pauls, President and CEO of DiaMedica. 'This recognition enhances our visibility among the broader investment community, supports increased institutional interest and ownership in our stock and serves as strong validation of our team's ability drive value for our shareholders.' DM199 for Preeclampsia KOL Replay DiaMedica also recently hosted a preeclampsia webinar featuring Prof. Baha Sibai, MD (University of Texas) Prof. Stephen Tong, MD, PhD (The University of Melbourne), Prof. Susan Walker, MD, PhD (The University of Melbourne), and who discussed the unmet need and current treatment landscape for preeclampsia (PE), a life-threatening pregnancy associated vascular disorder with no approved therapeutics. The Company plans to announce top-line Phase 2 results by mid-July. Click this link to listen to the replay About DiaMedica Therapeutics Inc. DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedica's lead candidate, DM199, is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company's website at
Business Insider
11 hours ago
- Business Insider
NioCorp to be added to Russell 3000 Index
NioCorp (NB) announced that it will be added as a member of the broad-market Russell 3000 Index, effective after the U.S. market opens on June 30 as part of the 2025 Russell indexes reconstitution. Confident Investing Starts Here:
Newsweek
3 days ago
- Newsweek
Mercedes Formula One Team Reports Massive $120 Million Revenue Boost
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Mercedes Formula One team has reported a significant revenue increase of approximately $120 million (as per today's exchange rates). Sixty percent of the earnings come from sponsorship and licensing. From the data published by the UK's Companies House, as published by Mercedes Grand Prix Limited, the parent company of the Mercedes F1 team, reported a turnover of approximately $856 million (£636 million) in 2024, which is a stark increase from 2023's $735 million (£546.5 million). Consequently, profits too have jumped significantly. Mercedes recorded an approximate $112.7 million (£83.8 million) net profit in 2023, with the number rising to $162 million (£120.34 million) in 2024, an increase of approximately $50 million. Mercedes' British driver George Russell pulls into pit lane after winning the 2025 Formula 1 Grand Prix du Canada at Circuit Gilles-Villeneuve in Montreal, Canada, on June 15, 2025. Mercedes' British driver George Russell pulls into pit lane after winning the 2025 Formula 1 Grand Prix du Canada at Circuit Gilles-Villeneuve in Montreal, Canada, on June 15, 2025. TIMOTHY A. CLARY/AFP/Getty Images It is noteworthy that Mercedes received a significant share of the F1 prize money for securing second place in the 2023 Constructors' Championship, which increased its revenue in 2024 since payments are processed the following year. As a result of the positive earnings, the team's three shareholders, Mercedes-Benz Group, team principal Toto Wolff, and Ineos, will receive an ordinary dividend of approximately $168 million (£125 million). However, it remains to be seen what impact Mercedes' performance in the 2024 season will have on its earnings, considering it secured fourth place in the championship. In addition, it would be interesting to see a change in the percentage of earnings from sponsorships, given seven-time world champion Lewis Hamilton's exit from the team after the 2024 season. Speaking of 2025, the season has been dominated by McLaren thus far. Mercedes achieved its first win in the previous round in Montreal, where the team's lead driver, George Russell, started from pole position and led the race for the majority of the laps to secure his first win of the year. However, rumors are doing the rounds that Russell is on Aston Martin's radar for the 2026 season, when the sport enters a new era of regulations. Newsweek Sports reported Russell's comments, who confirmed the interest shown by other teams but emphasized his intention to continue racing for Mercedes. He said: "No, I'm not talking with anybody else and any teams who have shown interest. I have been quite open to say my intentions are to stay with Mercedes. That's always been clear. "And, you know, I am loyal to Mercedes. They gave me this chance to get into Formula 1. There haven't been any hard feelings with any of the talks that have been going around, you know, especially around Max because, like I said numerous times, why wouldn't teams be interested in Max if everybody could, if every driver had a clean, no contracts for next year, Max would be the number one for every single team. And that's understandable. "But ultimately there are two seats for every race team and I knew if I continued to perform as I'm doing, my position would not be under threat whatsoever. So, I feel in a good place. We're in no rush to do contract negotiations."
